These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21059303)

  • 61. [Interferon treatment of chronic hepatitis C: basic immunobiology and immunopathology of the liver].
    Mazana JS
    Rev Esp Sanid Penit; 2013; 15(1):16-22. PubMed ID: 23529364
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hepatitis C virus infection in patients with hemophilia in Korea: Is antiviral therapy effective and safe?
    Rou WS; Lee BS
    Clin Mol Hepatol; 2015 Jun; 21(2):122-4. PubMed ID: 26157748
    [No Abstract]   [Full Text] [Related]  

  • 63. Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response.
    Heo J
    Korean J Hepatol; 2011 Sep; 17(3):180-2. PubMed ID: 22102383
    [No Abstract]   [Full Text] [Related]  

  • 64. Cognitive improvement after HCV eradication: Extending the benefits.
    Bajaj JS; Forton DM
    Hepatology; 2013 Aug; 58(2):480-2. PubMed ID: 23696270
    [No Abstract]   [Full Text] [Related]  

  • 65. Controlling hepatitis C with simeprevir.
    Dusheiko G
    Lancet Infect Dis; 2015 Jan; 15(1):2-4. PubMed ID: 25482331
    [No Abstract]   [Full Text] [Related]  

  • 66. Is the end of chronic hepatitis C virus infection in sight?
    McCaughan GW
    Med J Aust; 2012 Jun; 196(10):614. PubMed ID: 22676864
    [No Abstract]   [Full Text] [Related]  

  • 67. [High dose of pegylated interferon alpha-2a for the treatment of genotype1 chronic hepatitis C: a case report].
    Wu CH; Wang LF; Xu XY
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):873. PubMed ID: 21138646
    [No Abstract]   [Full Text] [Related]  

  • 68. Insulin resistance and diabetes mellitus in patients with chronic hepatitis C: spectators or actors?
    Petta S
    Dig Liver Dis; 2012 May; 44(5):359-60. PubMed ID: 22418268
    [No Abstract]   [Full Text] [Related]  

  • 69. [Chronic C virus infection management].
    García González N; Prieto Valtueña J
    Rev Clin Esp; 2003 Sep; 203(9):443-4. PubMed ID: 14563259
    [No Abstract]   [Full Text] [Related]  

  • 70. Beyond phase 3 registration trials: defining safety for triple therapy with protease inhibitors in cirrhosis.
    Ferenci P; Dusheiko G
    Gut; 2014 Jul; 63(7):1033-4. PubMed ID: 24334256
    [No Abstract]   [Full Text] [Related]  

  • 71. Proceed with caution: peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials.
    Kershenobich D; Muñoz L; Malé R; Gaytan J; Sánchez F
    Hepatology; 2010 Dec; 52(6):2240-1; author reply 2241-2. PubMed ID: 21105116
    [No Abstract]   [Full Text] [Related]  

  • 72. Hepatitis C treatment and alopecia totalis.
    Goh C
    J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S59-60. PubMed ID: 24326562
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
    Malgarini RB; Pimpinella G
    N Engl J Med; 2009 Apr; 360(18):1907; author reply 1908. PubMed ID: 19403910
    [No Abstract]   [Full Text] [Related]  

  • 74. Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C.
    Maekawa S; Enomoto N
    J Gastroenterol; 2014 Jan; 49(1):163-4. PubMed ID: 24356811
    [No Abstract]   [Full Text] [Related]  

  • 75. The effect of alanine aminotransferase dynamics on predicting sustained virological response in chronic hepatitis C virus infection.
    Kim TY
    Korean J Hepatol; 2012 Mar; 18(1):29-31. PubMed ID: 22511900
    [No Abstract]   [Full Text] [Related]  

  • 76. Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections.
    Torriani FJ; Chung RT
    ACP J Club; 2005; 142(1):A12; author reply A13. PubMed ID: 15656540
    [No Abstract]   [Full Text] [Related]  

  • 77. 1990-2010: two decades of interferon-based therapy.
    Buti M; Esteban R
    Clin Liver Dis; 2011 Aug; 15(3):473-82. PubMed ID: 21867931
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Alanine transaminase as a single marker is not reliable for selecting candidates of pegylated interferon and ribavirin treatment.
    Sharafi H; Alavian SM; Keshvari M
    J Formos Med Assoc; 2015 Feb; 114(2):195-6. PubMed ID: 24853983
    [No Abstract]   [Full Text] [Related]  

  • 79. Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation.
    Reddy KR; Everson GT
    Hepatology; 2013 Sep; 58(3):1181-4. PubMed ID: 23908010
    [No Abstract]   [Full Text] [Related]  

  • 80. Does the persistently normal aminotransferase levels in hepatitis C still have relevance?
    Méndez-Navarro J; Dehesa-Violante M
    Ann Hepatol; 2012; 11(3):412-4. PubMed ID: 22481464
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.